Welcome to our dedicated page for Biolargo SEC filings (Ticker: BLGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLargo, Inc. (OTCQX: BLGO) SEC filings page on Stock Titan provides access to the company’s official reports and current disclosures as filed with the U.S. Securities and Exchange Commission. These documents include Form 8-K current reports describing material events such as contract terminations, legal actions, investor presentations, and equity-related transactions, as well as other periodic and annual filings available through EDGAR.
For a cleantech and life sciences company like BioLargo, SEC filings offer detail on its technology portfolio, licensing and manufacturing agreements, and capital structure that may not appear in press releases alone. Recent 8-K filings, for example, describe the termination of a license and preferred master manufacturing agreement related to pet odor control products, potential impairment of a note receivable, and the filing of a federal lawsuit to protect patented CupriDyne odor control technology. Other 8-Ks discuss investor presentation materials for events such as LD Micro and NobleCon, and the conversion of unpaid salary and expenses by officers into locked-up common stock.
Through this page, users can review BioLargo’s disclosures about material agreements, legal proceedings, financial considerations tied to specific contracts, and corporate actions involving its common stock. Stock Titan enhances this access with AI-powered summaries that help explain the significance of complex filings, including key points from Form 8-K reports and other documents. Real-time updates from EDGAR, combined with AI-generated highlights, make it easier to track how BioLargo reports on its environmental technologies, medical subsidiaries, licensing relationships, and governance matters over time.
BioLargo, Inc. (BLGO) furnished investor presentation materials under Item 7.01 (Regulation FD). The company plans to present the slides attached as Exhibit 99.1 at the LD Micro Main Event XIX at the Hotel del Coronado in San Diego on October 20 at 2:00 p.m. Pacific Time.
The information in Item 7.01 and Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, is not incorporated by reference into other SEC filings, and may be updated through future public disclosures.
Jack B. Strommen, a director of BioLargo, Inc. (BLGO), received an option grant of 88,235 shares on 09/30/2025 under the company's 2024 Equity Incentive Plan. The option has an exercise price of $0.17 per share, is exercisable beginning 09/30/2025, and expires 09/30/2035. After this grant, Mr. Strommen directly beneficially owns 2,278,121 shares of common stock. The filing states the option was issued as payment for $15,000 of board fees for the most recently completed quarterly period. The Form 4 was signed by an attorney-in-fact on 10/02/2025 and is reported as an individual filing by one reporting person.
Linda Park, a director of Biolargo, Inc. (BLGO), received 110,294 stock options on 09/30/2025 at a $0.17 exercise price that vest/exercise beginning 09/30/2025 and expire 09/30/2035. The filing shows she now directly beneficially owns 1,164,025 shares of common stock after the reported transaction. The options were issued as payment for $18,750 of board fees under the Issuer's 2024 Equity Incentive Plan. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 10/02/2025.
Christina Elaine Bray, a director of Biolargo, Inc. (BLGO), received an option to purchase 110,294 shares of common stock at an exercise price of $0.17 per share on 09/30/2025. The option is exercisable on 09/30/2025 and expires on 09/30/2035. The filing reports that the option was issued as payment for $18,750 in director fees under the issuer's 2024 Equity Incentive Plan. After this grant, Ms. Bray beneficially owns 1,164,025 shares of Biolargo common stock, held directly. The Form 4 was executed on 10/02/2025 and filed under Section 16 reporting requirements.
Marshall Dennis E, a director of Biolargo, Inc. (BLGO), reported option grants on 09/30/2025. Two options to purchase common stock were acquired: 132,351 shares exercisable at $0.17 per share (expiring 09/30/2035) and 110,294 shares exercisable at $0.17 per share (expiring 09/30/2035). The first option replaces a previously issued option for 34,615 shares that expired unexercised; the replacement was made under the issuer’s Compensation Committee plan in lieu of $22,500 in services. The second option was issued as payment of $18,750 in board fees under the 2024 Equity Incentive Plan. Following the reported grants, beneficial ownership figures shown are 4,957,267 and 5,067,561 shares on the respective lines. The Form 4 was signed by attorney-in-fact John R. Browning on 10/02/2025.
BioLargo, Inc. disclosed that its long‑standing license and manufacturing relationship with Pooph Inc. has broken down, and it has issued notice revoking Pooph’s license and terminating the License Agreement with 150 days’ notice after Pooph failed to pay agreed royalties and product invoices. Pooph has stated it will stop ordering from BioLargo, pursue its own formula for Pooph‑branded products, and terminate the Preferred Master Manufacturing Agreement, which BioLargo disputes, citing its contractual right to withhold product when payment terms were not met.
BioLargo also reported that a $3,486,000 note receivable tied to Pooph royalties and product invoices on its June 30, 2025 balance sheet may need to be written down, and management expects any impairment of this asset to be substantial, signaling a potentially significant financial hit related to this customer relationship.